News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Michael Wang: Strong antitumor synergy between venetoclax and A1155463
Jul 19, 2024, 22:19

Michael Wang: Strong antitumor synergy between venetoclax and A1155463

Michael Wang, Professor in the Department of Lymphoma/Myeloma and the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center, shared a post on X :

“In Blood Advances, Dolnikova et al of Prague’s Charles University show strong antitumor synergy between the BCL2 inhibitor venetoclax and the BCL-XL inhibitor A1155463 that is preserved even with knockout of BCL2L11. True for MCL, DLBCL, and others.”

Michael Wang

Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status published in Blood Advances

Autors: Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener

Michael Wang

Source: Michael Wang/X

A1155463 Alexandra Dolnikova bcl-2 inhibitor blood advances cancer Charles University Cristina Daniela Kelemen Dana Sovilj DLBCL Dmitry Kazantsev Eva Hoferkova Eva Pokorna Karel Helman Katerina Machova Polakova Ladislav Andera Liliana Tuskova Magdalena Klanova Marek Mraz Marek Trneny MCL Nikola Curik OncoDaily Oncology Pavel Klener venetoclax
Special Coverage
Science
Jan 30, 2025, 13:35
Myeloma Paper of the Day, January 30th, suggested by Robert Orlowski
Blog
Jan 30, 2025, 13:27
Registration is open for the Updates in Amyloidosis Conference
Blog
Jan 30, 2025, 11:56
Emirates Oncology Society - The exploratory biomarker analysis of the Phase 3 KEYNOTE-522 study
Blog
Jan 30, 2025, 11:54
Thomas Savy: Cancer evolution - from Darwin to the Extended Evolutionary Synthesis
Blog
Jan 30, 2025, 11:52
Douglas Flora: Ctrl+Alt+Cure - Rebooting Cancer Care
Blog
Jan 30, 2025, 11:48
How lessons from C/Can’s global network of cities can support the EU Mission on Cancer’s objectives
Opinion
Jan 30, 2025, 11:37
UICC held its first Board meeting of 2025 in Geneva, Switzerland
Blog
Jan 30, 2025, 11:29
Navneet Majhail: Access barriers to anti-CD19+ CART therapies for lymphoma
Blog
Jan 30, 2025, 10:52
Wafaa M. Rashed: Celebrating Milestones in Policy Advocacy
Blog
Jan 30, 2025, 10:48
The potential of BOT/BAL for patients who previously had limited treatment options - Agenus
Blog
Jan 30, 2025, 09:16
Esranur Aydın: Some cases change the way we think about treatment
Blog
Jan 30, 2025, 09:14
Pashtoon Kasi: Treatment Strategies for Liver Metastases - Insights from a GI25 Study